```
=> d que
L13           5 SEA FILE=CAPLUS ABB=ON  PLU=ON  58431-88-2/RN


=> d ti 1-5

L13  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Compounds for inhibiting diseases and preparing cells for transplantation

L13  ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Compositions and methods for treating amyloidosis

L13  ANSWER 3 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Methods and compositions to treat glycosaminoglycan-associated molecular
     interactions

L13  ANSWER 4 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Copolyester polymer of enhanced dyeability

L13  ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Reaction of 1,3-propane and 1,4-butane sultones with some amines


=> d bib ab 2

L13  ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2000:772432  CAPLUS
DN   133:329624
TI   Compositions and methods for treating amyloidosis
IN   Gordon, Heather; Szarek, Walter; Weaver, Donald; Kong, Xianqi
PA   Queen's University at Kingston, Can.; Neurochem, Inc.
SO   PCT Int. Appl., 68 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2000064420      A2   20001102       WO 2000-CA494    20000428
     WO 2000064420      A3   20021107
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
             LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
             SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     BR 2000010099      A    20020604       BR 2000-10099    20000428
     EP 1276483         A2   20030122       EP 2000-922395   20000428
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003517458      T2   20030527       JP 2000-613411   20000428
PRAI US 1999-131464P    P    19990428
     US 1999-135545P    P    19990524
     US 1999-143123P    P    19990709
     WO 2000-CA494      W    20000428
OS   MARPAT 133:329624
AB   Therapeutic compds. and methods for modulating amyloid aggregation in a
     subject, whatever its clin. setting, are described.  Amyloid aggregation
     is modulated by the administration to a subject of an effective amt. of a
     therapeutic compd. [(R1Zk)(R2Qm)N]pTYs [R1, R2 = H, (un)substituted alkyl,
     (un)substituted aryl; Z, Q = C(O), C(S), SO2, SO; k, m = 0, 1, with
     provisions; p, s = pos. integer such that biodistribution of therapeutic
     compd. for intended target site is not prevented while maintaining
     activity of therapeutic compd.; T = linking group; Y = AX; A = anionic
```

group at physiol. pH; X = cationic group], or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. Prepn. of e.g. 8-methoxy-5-quinolinesulfonic acid sodium salt is described.

=> d ind

L13 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM A61K031-00
CC 1-10 (Pharmacology)
Section cross-reference(s): 27, 63
ST amyloidosis treatment; islet amyloid polypeptide amyloidosis; transplant cell amyloidosis treatment compn
IT Protein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(amylin; compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT Pancreatic islet of Langerhans
(amyloidosis; compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT Pancreatic islet of Langerhans
(compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT Transplant and Transplantation
(pancreatic islet; compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT Pancreatic islet of Langerhans
(transplant; compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT 309752-14-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT 303957-01-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 100-88-9, Cyclohexanesulfamic acid 376-73-8, Hexafluoroglutaric acid 407-41-0 7013-33-4
14099-81-1, 1,2,3,4-Tetrahydroisoquinoline hydrochloride 22458-67-9, Cyclohexanesulfamic acid sodium salt 29777-99-9 40712-20-7,
8-Methoxy-5-quinolinesulfonic acid **58431-88-2** 76326-31-3
303957-00-8, 5-Quinolinesulfonic acid, 8-methoxy-, sodium salt
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds. for inhibiting amyloidosis and prepg. cells for transplantation)
IT 939-23-1, 4-Phenylpyridine 1120-71-4, 1,3-Propane sultone
RL: RCT (Reactant); RACT (Reactant or reagent)
(compds. for inhibiting amyloidosis and prepg. cells for transplantation)

=> d bib ab 3

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:98288 CAPLUS
DN 132:132322
TI Methods and compositions to treat glycosaminoglycan-associated molecular interactions

IN Kisilevsky, Robert; Green, Allan M.; Gervais, Francine
PA Neurochem, Inc., Can.; Queen's University at Kingston
SO PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000006133 | A2 | 20000210 | WO 1999-IB1473 | 19990728 |
| | WO 2000006133 | A3 | 20000817 | | |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6310073 | B1 | 20011030 | US 1999-362505 | 19990727 |
| | CA 2338705 | AA | 20000210 | CA 1999-2338705 | 19990728 |
| | AU 9951894 | A1 | 20000221 | AU 1999-51894 | 19990728 |
| | EP 1100487 | A2 | 20010523 | EP 1999-936931 | 19990728 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | US 2002193395 | A1 | 20021219 | US 2001-970148 | 20011002 |
| PRAI | US 1998-94454P | P | 19980728 | | |
| | US 1999-362505 | A | 19990727 | | |
| | WO 1999-IB1473 | W | 19990728 | | |

OS MARPAT 132:132322
AB Therapeutic compds. and methods for inhibiting a glycosaminoglycan (GAG)-assocd. mol. interaction in a subject, whatever its clin. setting, are described. The glycosaminoglycan-assocd. mol. interaction may be e.g. the interaction assocd. with a bacterial or viral infection. The compds. of the invention include Q(Y-X+)n (Q = carrier mol.; Y- = anionic group at physiol. pH; X+ = cationic group; n = integer such that the biodistribution of the therapeutic compd. for an intended target site is not prevented while maintaining activity of the therapeutic compd.) and pharmaceutically acceptable salts and esters thereof.

=> d ind 3

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM A61K031-00
CC 1-5 (Pharmacology)
Section cross-reference(s): 63
ST glycosamine assocd interaction therapeutic; bacterial infection glycosamine assocd interaction therapeutic; virus infection glycosamine assocd interaction therapeutic
IT Carbohydrates, biological studies
Peptides, biological studies
Polymers, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(carrier mol.; methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)
IT Bacteria (Eubacteria)
Virus
(cell-surface interaction; methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)
IT Infection
(infectious agent interaction; methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)
IT Antibacterial agents
Antiviral agents
Bordetella pertussis

Chlamydia
Chlamydia trachomatis
Cytomegalovirus
Drug delivery systems
Herpesviridae
Human herpesvirus
Legionella pneumophila
Molecular association
Mycoplasma pneumoniae
Pseudomonas aeruginosa
Staphylococcus aureus
(methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)

IT Eotaxin
Glycosaminoglycans, biological studies
Interleukin 8
RANTES (chemokine)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)

IT 407-41-0, O-Phospho-L-serine 1119-23-9 1119-23-9D, esters 1119-71-7 1119-71-7D, esters 1119-99-9 1119-99-9D, esters 1135-40-6 1984-15-2, Methylene diphosphonic acid 3687-18-1, 3-Amino-1-propanesulfonic acid 3687-18-1D, 3-Amino-1-propanesulfonic acid, esters 6165-68-0, 2-Thiopheneboronic acid 6419-19-8 13501-35-4 13501-35-4D, esters 14650-46-5 21668-77-9, 1,3-Propanedisulfonic acid 21668-77-9D, 1,3-Propanedisulfonic acid, esters 25053-27-4 29777-99-9D, esters 34700-81-7 **58431-88-2** 58431-88-2D, esters 63555-51-1 63555-51-1D, esters 63585-09-1, Trisodium phosphonoformate 108084-41-9 114108-96-2 172324-98-0 256954-42-4 256954-43-5 256954-43-5D, esters 256954-44-6 256954-44-6D, esters 256954-45-7 256954-45-7D, esters 256954-46-8 256954-46-8D, esters 256954-47-9D, esters 256954-48-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)

IT 9005-49-6, Heparin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods and compns. to treat glycosaminoglycan-assocd. mol. interactions)

=> d bib ab 4

L13 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:486277 CAPLUS
DN 87:86277
TI Copolyester polymer of enhanced dyeability
IN McNeely, Gerald W.
PA Akzona, Inc., USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 4029638 | A | 19770614 | US 1975-572025 | 19750428 |

PRAI US 1975-572025 19750428

AB Cationic dyeable polyester fibers were manufd. from alkali metal salts of sulfonated sulfonamides, ethylene glycol (I), and dimethyl terephthalate (II). Thus, N-(6-hydroxyhexyl)-N-(3-sulfopropyl)-3-carbomethoxybenzenesulfonamide Na salt (III) [63541-84-4] 14.2, I 241, II

294, and Mn benzoate 0.262 part were heated 1h to 220.degree., mixed with 0.30 part Sb tributylate and 0.994 part OP(OMe)3, and heated to 265.degree. at 0.1mm to give a polyester [63541-85-5] with intrinsic viscosity 0.38. The polymer was spun and drawn as 30/6 yarn which had intrinsic viscosity 0.31, tenacity 3.34 g/denier, breaking elongation 50.6%. Yarn dyed in 3 basic dye baths with >90% exhaustion gave good to excellent lightfastness ratings after 10, 20, and 40 h carbon arc Fadeometer exposure.

=> d bib ab 5

L13 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1976:89557 CAPLUS
DN 84:89557
TI Reaction of 1,3-propane and 1,4-butane sultones with some amines
AU Mozolis, V.; Rastenyte, L.
CS Inst. Chem. Chem. Technol., Vilnius, USSR
SO Lietuvos TSR Mokslu Akademijos Darbai, Serija B: Chemija, Technika, Fizine Geografija (1975), (4), 77-84
CODEN: LMDBAL; ISSN: 0132-2729
DT Journal
LA Russian
AB RR1N(CH2)3SO3H [R = HOCH2CH2, HO(CH2)3, p-MeOC6H4, C(:NH)NH2, C(:NH)NHCN, o-H2NC6H4, NaO3SCH2CH2, p-NaO3SC6H4, R1 = H; R = R1 = HOCH2CH2] were prepd. in 22.0-91.4% yields by boiling 1,3-propanesultone with an amine 1 hr. Analogously obtained were 70.7-88.6% RR1N(CH2)4SO3H [R = HOCH2CH2,/ HO(CH2)3, R1 = H; R = R1 = HOCH2CH2].

```
=> d que
L1          3650 SEA FILE=CAPLUS ABB=ON  PLU=ON  CLARK A?/AU
L2           414 SEA FILE=CAPLUS ABB=ON  PLU=ON  FRASER P?/AU
L3            17 SEA FILE=CAPLUS ABB=ON  PLU=ON  VERCHERE B?/AU
L4          4332 SEA FILE=CAPLUS ABB=ON  PLU=ON  GUPTA A?/AU
L5            12 SEA FILE=CAPLUS ABB=ON  PLU=ON  MIGNEAULT D?/AU
L6           246 SEA FILE=CAPLUS ABB=ON  PLU=ON  SZAREK W?/AU
L7          8529 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5 OR
                 L6)
L8            34 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 AND TRANSPLANT?
L9            12 SEA FILE=CAPLUS ABB=ON  PLU=ON  L8 AND INHIBIT?
L10            3 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 AND AMYLOID
L11           16 SEA FILE=REGISTRY ABB=ON  PLU=ON  (100-88-9/BI OR 1120-71-4/BI
                 OR 14099-81-1/BI OR 22458-67-9/BI OR 29777-99-9/BI OR 303957-00
                 -8/BI OR 303957-01-9/BI OR 309752-14-5/BI OR 376-73-8/BI OR
                 407-41-0/BI OR 40712-20-7/BI OR 58431-88-2/BI OR 7013-33-4/BI
                 OR 76326-31-3/BI OR 91-21-4/BI OR 939-23-1/BI)
L12            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L10 AND L11
L14         6753 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11
L15           21 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 AND TRANSPLANT?/OBI
L16            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L15 AND AMYLO?
L17           20 SEA FILE=CAPLUS ABB=ON  PLU=ON  L15 NOT L16
L18           11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L17 AND PY<2001
L19           11 SEA FILE=CAPLUS ABB=ON  PLU=ON  L18 NOT L12


=> d ibib abs hitstr 1-11

L19  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2000:814461  CAPLUS
DOCUMENT NUMBER:          133:362707
TITLE:                    Preparation of pyridylethylpyridines as
                          phosphodiesterase 4 inhibitors.
INVENTOR(S):              Cote, Bernard; Friesen, Richard; Frenette, Richard;
                          Girard, Mario; Girard, Yves; Godbout, Cedrickx; Guay,
                          Daniel; Hamel, Pierre; Blouin, Marc; Ducharme, Yves;
                          Prescott, Sylvie
PATENT ASSIGNEE(S):       Merck Frosst Canada & Co., Can.
SOURCE:                   PCT Int. Appl., 155 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2000068198      A2   20001116       WO 2000-CA500    20000503 <--
     WO 2000068198      A3   20010405
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
             ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
             MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
             SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6200993         B1   20010313       US 2000-551040   20000417
     EP 1177175         A2   20020206       EP 2000-922400   20000503
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     AU 764258          B2   20030814       AU 2000-42829    20000503
PRIORITY APPLN. INFO.:                    US 1999-132532P  P  19990505
                                          WO 2000-CA500    W  20000503
OTHER SOURCE(S):          MARPAT 133:362707
GI
```



I

AB Title compds. [I; Y = N, NO; R1, R2 = H, alkyl, haloalkyl; R3, R4 = H, alkyl; R3R4 = O, atoms to form a 5-7 membered carbocyclic ring; R5 = null, H, (substituted) alkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, O; R3R5 = atoms to form a 5-6 membered heterocyclic ring; dotted line = optional double bond; R6, R7 = H, halo, alkyl, haloalkyl, cyano; n = 0-6], were prepd. Thus, 4-[2-[3,4-bis(difluoromethoxy)phenyl]-2-(6-bromo-3-pyridyl)ethyl]pyridine (prepn. given) was heated with PhCH2NH2 and CuI to give 72% 4-[2-[3,4-bis(difluoromethoxy)phenyl]-2-[6-(benzylamino)-3-pyridyl]ethyl]pyridine. The latter inhibited PDE 4 with IC50 = 0.75 nM.

IT **91-21-4**, 1,2,3,4-Tetrahydroisoquinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)

RN 91-21-4 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:742117 CAPLUS

DOCUMENT NUMBER: 133:296665

TITLE: Preparation of amidine- or guanidine-containing peptidomimetics for use as inhibitors of complement proteases

INVENTOR(S): Hillen, Heinz; Schmidt, Martin; Mack, Helmut; Seitz, Werner; Haupt, Andreas; Zechel, Johann-Christian; Kling, Andreas

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000061608 | A2 | 20001019 | WO 2000-EP2710 | 20000328 <-- |
| WO 2000061608 | A3 | 20010111 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| EP 1169338 | A2 | 20020109 | EP 2000-920597 | | 20000328 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | | |
| TR 200102913 | T2 | 20020121 | TR 2001-20010291 | | 20000328 |
| BR 2000009678 | A | 20020122 | BR 2000-9678 | | 20000328 |
| JP 2002542164 | T2 | 20021210 | JP 2000-611550 | | 20000328 |
| US 6683055 | B1 | 20040127 | US 2000-539811 | | 20000330 |
| ZA 2001007978 | A | 20030107 | ZA 2001-7978 | | 20010928 |
| BG 105978 | A | 20020731 | BG 2001-105978 | | 20011004 |
| NO 2001004876 | A | 20011204 | NO 2001-4876 | | 20011008 |

PRIORITY APPLN. INFO.: DE 1999-19915930 A 19990409
WO 2000-EP2710 W 20000328

OTHER SOURCE(S): MARPAT 133:296665

GI



I

AB The invention relates to synthesis of title compds., e.g. [I; R = cyclohexyl(II) or R = cyclohexylmethyl(III)], for use as inhibitors of the complement proteases C1s and C1r in treatment of disease. Compd. III was synthesized in seven steps, beginning with (D)-cyclohexylalanine Me ester hydrochloride and 4-nitrobenzylsulfonyl chloride, and including reaction with 3,4-dehydroprolyl-(3-(6-cyano)picolyl)-amide and conversion of the cyano group to the amidine. In in vivo expts. II had IC50's for C1s and C1r resp. of 0.6 and 0.9 .mu.mol/l.

IT **1120-71-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

RN 1120-71-4 CAPLUS

CN 1,2-Oxathiolane, 2,2-dioxide (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:614254 CAPLUS

DOCUMENT NUMBER: 129:302563

TITLE: Preparation of piperidines and their analogs as neurokinin antagonists for treatment of diseases

INVENTOR(S): Carruthers, Nicholas I.; Alaimo, Cheryl A.

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 10251228 | A2 | 19980922 | JP 1997-51901 | 19970306 <-- |

PRIORITY APPLN. INFO.: JP 1997-51901 19970306
OTHER SOURCE(S): MARPAT 129:302563
GI



I

AB The compds. I [i, j = 1, 2; n = 0-3; n' = 1-3; A = A' = H; AA' may form O, S, substituted imino; X = O, CO, (un)substituted CH2, (un)substituted NH, S, SO, SO2; R2, R3 = H, halo, C1-6 alkyl, CF3, OH, alkoxy, (un)substituted Ph, NO2, etc.] or pharmacol. acceptable salts are prepd. I are useful for treatment of asthma, allergy, psoriasis, rheumatoid arthritis, migraine headache, depression, Alzheimer's disease, gastrointestinal disorders, pain, etc. Hydrogenation of 2.0 g 3,4-dichloro-.beta.-(2-oxoethyl)-N-methyl-N-phenylbenzenepropanamide with NaBH3CN at room temp. for 18 h gave 0.42 g .beta.-(3,4-dichlorophenyl)-4-hydroxy-N-methyl-N,4-diphenyl-1-piperidinepentamide, which showed Ki of 150 nM and 5.2 nM for NK1 and Nk2 receptor binding, resp.

IT **91-21-4**, 1,2,3,4-Tetrahydroisoquinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of piperidines as neurokinin antagonists for treatment of diseases)

RN 91-21-4 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:44761 CAPLUS
DOCUMENT NUMBER: 126:59877
TITLE: Preparation of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compounds as inhibitors of phosphodiesterase IV and tumor necrosis factor.
INVENTOR(S): Montana, John; Dyke, Hazel Joan; Maxey, Robert James; Lowe, Christopher
PATENT ASSIGNEE(S): Chiroscience Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9636611 | A1 | 19961121 | WO 1996-GB1203 | 19960520 <-- |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML | | | | |
| AU 9657721 | A1 | 19961129 | AU 1996-57721 | 19960520 <-- |
| ZA 9603999 | A | 19970520 | ZA 1996-3999 | 19960520 <-- |
| US 5728712 | A | 19980317 | US 1996-650672 | 19960520 <-- |

PRIORITY APPLN. INFO.: GB 1995-10184 A 19950519
GB 1995-20419 A 19951006
WO 1996-GB1203 W 19960520

OTHER SOURCE(S): MARPAT 126:59877

GI



I

AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl; R2 = (halo-substituted) alkyl; R3R4N = (substituted) 5-7 membered heterocyclyl which is fused to a carbocyclic, arom., heterocyclic or heteroarom. ring; with provisos], were prepd. as inhibitors of phosphodiesterase IV and tumor necrosis factor (no data). Thus, 1,2,3,4-tetrahydroisoquinoline, 3,4-dimethoxybenzenesulfonyl chloride, and Et3N were stirred 24 h in CH2Cl2 to give N-(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroquinoline.

IT **91-21-4**, 1,2,3,4-Tetrahydroisoquinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

RN 91-21-4 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




L19 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:34995 CAPLUS
DOCUMENT NUMBER: 126:162158
TITLE: Novel anti-calcification treatment of biological tissues by grafting of sulfonated polyethylene oxide
AUTHOR(S): Park, Ki Dong; Lee, Won Kyu; Yun, Ju Young; Han, Dong Keun; Kim, Soo Hyun; Kim Young Ha; Kim, Hyoung Mook; Kim, Kwang Taek
CORPORATE SOURCE: Polymer Chem. Lab., Korea Inst. Sci. Technol., Seoul, 130-650, S. Korea
SOURCE: Biomaterials (1997), 18(1), 47-51
CODEN: BIMADU; ISSN: 0142-9612
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Biol. porcine tissue was modified by the direct coupling of sulfonated polyethylene oxide (PEO-SO3) contg. amino end groups after glutaraldehyde fixation. The calcification of the modified tissue [bioprosthetic tissue (BT)-PEO-SO3] and control (BT control) was investigated by in vivo rate subdermal, canine aorta-illiac shunt and right ventricle-pulmonary artery shunt implantation models. Less calcium deposition of BT-PEO-SO3 than of BT control was obsd. in in vivo tests. Such a reduced calcification of BT-PEO-SO3 can be explained by decreases of residual glutaraldehyde groups, a space filling effect and, therefore, improved biostability and synergistic blood-compatible effects of PEO and SO3 groups after the covalent binding of PEO-SO3 to tissue. This simple method can be a useful anti-calcification treatment for implantable tissue valves.

IT **1120-71-4D**, Propanesultone, reaction products with PEG
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(anticalcification treatment of biol. tissues by grafting of sulfonated polyethylene oxide)

RN 1120-71-4 CAPLUS

CN 1,2-Oxathiolane, 2,2-dioxide (8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:767627 CAPLUS
DOCUMENT NUMBER: 124:21803
TITLE: Method and agents for preventing tissue injury from hypoxia
INVENTOR(S): Bursten, Stuart L.; Singer, Jack W.; Rice, Glenn C.
PATENT ASSIGNEE(S): CE Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9513075 | A1 | 19950518 | WO 1994-US12821 | 19941114 <-- |
| W: AU, CA, JP | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9510907 | A1 | 19950529 | AU 1995-10907 | 19941114 <-- |
| EP 728003 | A1 | 19960828 | EP 1995-901808 | 19941114 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |

PRIORITY APPLN. INFO.: US 1993-152117 A 19931112
WO 1994-US12821 W 19941114

OTHER SOURCE(S): MARPAT 124:21803

GI



I

AB Tissue injury, caused by tissue hypoxia and reoxygenation, is prevented by administering a xanthine deriv. I [R1 = (.omega.-1) secondary alc.-substituted C5-12 alkyl enantiomer; R2, R3 = C1-12 alkyl or (di)oxaalkyl] or a (heterocyclylalkyl)amine that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid through inhibition of lysophosphatidic acyltransferase. Diseases that can be treated with these compds. include shock, sequelae of myocardial infarction and stroke, altitude sickness, acidosis, hypoxia-mediated neurodegenerative diseases, and disorders related to transplantation and transplant rejection. Thus, in mice with exptl. hemorrhage, treatment with lisophylline (100 mg/kg i.v. after 1 h, then 100 mg/kg i.p. 8 times at 8-h intervals) largely normalized signs of hemorrhagic shock (neutrophil infiltration, interstitial edema, elevated plasma levels of interferon-.gamma. and tumor necrosis factor .alpha., elevated mRNA levels for interleukins 1.beta. and 6 in pulmonary mononuclear cells, etc.).

IT **91-21-4D**, aminoalkyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and agents for preventing tissue injury from hypoxia)

RN 91-21-4 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




L19 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:227140 CAPLUS
DOCUMENT NUMBER: 122:151367
TITLE: Compounds for treatment of proliferative diseases mediated by second messengers
INVENTOR(S): Leigh, Alistair; Michnick, John; Kumar, Anil; Underiner, Gail; Rice, Glenn C.; Klein, J. Peter; Reddy, Dandu
PATENT ASSIGNEE(S): Cell Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9422449 | A1 | 19941013 | WO 1994-US3610 | 19940401 <-- |
| W: AU, CA, JP | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 5670506 | A | 19970923 | US 1993-42946 | 19930405 <-- |
| AU 9466238 | A1 | 19941024 | AU 1994-66238 | 19940401 <-- |
| EP 714302 | A1 | 19960605 | EP 1994-914005 | 19940401 <-- |
| R: DE, FR, GB, IT | | | | |

PRIORITY APPLN. INFO.: US 1993-42946 19930405
WO 1994-US3610 19940401
OTHER SOURCE(S): MARPAT 122:151367

AB Carbocyclic and heterocyclic compds. with 5-7 ring atoms are prepd. which are useful as antiproliferative agents for treatment and prevention of diseases mediated by 2nd-messenger pathways. Thus, 1-(6-chloro-5-oxohexyl)-3,7-dimethylxanthine at 100 .mu.M inhibited by 88% the degranulation of mast cells in response to allergen challenge and strongly inhibited growth of Saccharomyces cerevisiae, an indication of potential topical or systemic antimicrobial activity.

IT **91-21-4DP**, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for treatment of proliferative diseases mediated by second messengers)
RN 91-21-4 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:144618 CAPLUS
DOCUMENT NUMBER: 118:144618
TITLE: Phosphorus metabolite characterization of human prostatic adenocarcinoma in a nude mouse model by phosphorus-32 magnetic resonance spectroscopy and high pressure liquid chromatography
AUTHOR(S): Kurhanewicz, John; Dahiya, Rajvir; Macdonald, Jeffrey M.; Jajodia, Prahalad; Chang, Lee Hong; James, Thomas L.; Narayan, Perinchery
CORPORATE SOURCE: Sch. Med., Univ. California, San Francisco, CA, 94143-0738, USA
SOURCE: NMR in Biomedicine (**1992**), 5(4), 185-92
CODEN: NMRBEF; ISSN: 0952-3480
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of expts. were conducted to identify and quantify the phosphorus metabolites of DU 145 xenografts (a human prostatic adenocarcinoma cell line grown in nude mice) using 31P MRS and HPLC. The 131P spectral characteristics of DU 145 xenografts were compared to perfused DU 145 cells and to in situ human prostatic adenocarcinomas. These studies demonstrated that both DU 145 xenografts and perfused DU 145 cells exhibited reduced levels of phosphocreatine relative to spectra of in situ human prostatic adenocarcinomas. Elevated levels of phosphomonesters (PMEs) were obsd. in 31P spectra of both DU 145 xenografts and in situ human prostatic adenocarcinomas. The major components of the PME resonance of Du 145 xenografts were identified as phosphocholine and phosphoethanolamine. High levels of diphosphodiesters (DPDEs) were consistently obsd. for both DU 145 xenografts and perfused DU 145 cells, but were absent in 31P spectra of in situ primary human adenocarcinomas. In agreement with spectroscopic results, high pressure liq. chromatog. analyses of human tissue removed at surgery contained insignificant amts. of DPDEs while DU 145 xenografts had high levels of DPDEs consistently mainly of uridine-5'-diphospho-N-acetylgalactosamine (22.4 nmol/mg protein) and uridine-5'-diphospho-N-acetylglucosamine (7.4 nmol/mg protein).
IT **407-41-0**
RL: BIOL (Biological study)
(of prostate gland adenocarcinoma cultured cells and xenotransplants in nude mouse and in situ from tissues of human, NMR spectroscopy and HPLC in study of)
RN 407-41-0 CAPLUS
CN L-Serine, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:589189 CAPLUS
DOCUMENT NUMBER: 117:189189
TITLE: Levels of phosphoserine, phosphothreonine and prostaglandins in a rat **transplantable** hepatoma and prostatic tumor
AUTHOR(S): Levine, L.; Van Vunakis, H.
CORPORATE SOURCE: Dep. Biochem., Brandeis Univ., Waltham, MA, 02254, USA
SOURCE: Developments in Oncology (**1991**), 67(Eicosanoids Other Bioact. Lipids Cancer Radiat. Inj.), 353-7
CODEN: DEONDS; ISSN: 0167-4927
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To investigate the possible relationship between putative oncogene product and growth factor receptor kinase activity-assocd. phosphorylation and prostaglandin formation, the authors measured phosphoserine and phosphothreonine residues and prostaglandin content in hepatoma and prostate tumor transplants in rats.
IT **407-41-0**
RL: BIOL (Biological study)
(of hepatoma and prostate tumor tissues, phosphothreonine and prostaglandins in relation to)
RN 407-41-0 CAPLUS
CN L-Serine, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L19 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:465125 CAPLUS
DOCUMENT NUMBER: 117:65125
TITLE: Purification and characterization of a 65-kDa tumor-associated phosphoprotein from rat **transplantable** hepatocellular carcinoma 1682C cell line
AUTHOR(S): Mirowski, Marek; Sherman, Ute; Hanausek, Malgorzata
CORPORATE SOURCE: M. D. Anderson Cancer Cent., Univ. Texas, Smithville, TX, 78957, USA
SOURCE: Protein Expression and Purification (**1992**), 3(3), 196-203
CODEN: PEXPEJ; ISSN: 1046-5928
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A homogeneous tumor-assocd. phosphoglycoprotein of about 65 kDa (p65) was isolated by ammonium sulfate pptn. of proteins from conditioned medium contg. the rat transplantable hepatocellular carcinoma 1682C cell line, followed by high-performance liq. chromatog. on mol.-sieving and Ph hydrophobic interaction columns. The protein was concd. in a Rotofor isoelec. focusing cell and finally sepd. by isoelectrofocusing followed by SDS-polyacrylamide gel electrophoresis. A purifn. of approx. 11,000-fold was achieved after the Rotofor concn. step. This protein migrated as a single band upon electrophoresis in SDS-PAGE and had a pI of 5.8 in isoelectrofocusing gels. The carbohydrate content of the blotted phosphoglycoprotein was analyzed by probing the blots with biotinylated lectins; a pos. reaction was detected with Con A, wheat-germ agglutinin, and Ricinus communis agglutinin. To confirm the tumor origin of this mol., hepatocellular carcinoma cells were labeled in vivo using [32P]orthophosphate as well as [35S]methionine and cell culture medium was

analyzed for the presence of radioactive band that corresponds with the protein. Phosphoamino acid anal. by thin-layer chromatog. showed the presence of phosphotyrosine, phosphothreonine, and phosphoserine, which was later confirmed by anal. of the amino acid compn. Using the method described by J. J. Marchalonis and J. K. Weltman (1971) for comparative anal. of protein structure and evolution, the protein isolated here was compared with other tumor markers and proteins showing similar properties and no significant similarities were found.

IT **407-41-0**
RL: BIOL (Biological study)
(of glycophosphoprotein p65, of hepatocellular carcinoma)

RN 407-41-0 CAPLUS
CN L-Serine, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:422482 CAPLUS
DOCUMENT NUMBER: 95:22482
TITLE: Retrieval analysis of calcific degeneration of prosthetic tissue valves: the role of vitamin K-dependent processes and other regulatory mechanisms
AUTHOR(S): Levy, Robert J.; Sanders, Stephen P.; Lian, Jane B.
CORPORATE SOURCE: Med. Cent., Child. Hosp., Boston, MA, 02115, USA
SOURCE: NBS Special Publication (United States) (**1981**), 601, 339-48
CODEN: XNBSAV; ISSN: 0083-1883
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Calcification of prosthetic glutaraldehyde preserved porcine xeno-graft valves was found to be assocd. with calcification, and this complication occurred only in patients under 15 yr of age at the time of valve replacement. Amino acid anal. of calcified leaflet tissue revealed the presence of high levels of proteins contg. vitamin K-dependent, Ca2+-binding .gamma.-carboxyglutamic acid (Gla), in mineralized specimens, with no Gla present in noncalcified valve tissue. Ca2+-binding was also detected in relatively greater amts. in the mineralized specimens, compared to control. Calcified xenografts also demonstrated a relative redn. in collagen content. The implications that vitamin K-antagonism could be of benefit in treating or preventing prosthesis calcification is discussed.

IT **407-41-0**
RL: BIOL (Biological study)
(of ischemic heart valve xenograph calcification)

RN 407-41-0 CAPLUS
CN L-Serine, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ind 11

L19 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN

CC 14-4 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
ST heart xenotransplant calcification vitamin K; carboxyglutamate heart xenotransplant calcification; phosphoserine heart xenotransplant calcification; collagen heart xenotransplant calcification
IT Collagens, biological studies
RL: BIOL (Biological study)
(in ischemic heart valve xenograph calcification)
IT **Transplant** and **Transplantation**, animal
(of xenograft heart valve, calcification of)
IT Heart
(valve, calcification of xenograft of)
IT 12001-79-5
RL: BIOL (Biological study)
(heart valve xenotransplant calcification relevancy to)
IT **407-41-0**
RL: BIOL (Biological study)
(of ischemic heart valve xenograph calcification)
IT 56271-99-9
RL: BIOL (Biological study)
(of proteins, in ischemic heart valve xenograph calcification)

=> d ind 1-10

L19 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM C07D213-89
ICS C07D213-74; C07D417-14; C07D401-14; C07D409-14; C07D213-79; C07D213-76; C07D405-14; A61K031-4427; A61P011-00
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
ST pyridylethylpyridine prepn phosphodiesterase inhibitor; fluoromethoxyphenylbenzylaminopyridylethylpyridine prepn phosphodiesterase inhibitor
IT Intestine, disease
(Crohn's, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Respiratory distress syndrome
(adult, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Eye, disease
(allergic conjunctivitis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Nose
(allergic rhinitis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Spinal column
(ankylosing spondylitis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Antiarteriosclerotics
(antiatherosclerotics; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Dermatitis
(atopic, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Bronchi
(chronic bronchitis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Granuloma
(eosinophilic, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Kidney, disease
(glomerulonephritis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT **Transplant** and **Transplantation**
(graft-vs.-host reaction, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)

IT Lung, disease
Respiratory tract
(inflammation, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Cachexia
(inhibitors; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Reperfusion
(injury, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Inflammation
(neurogenic, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Analgesics
Antiarthritics
Antiasthmatics
Antidepressants
Antitumor agents
Antitussives
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Skin, disease
(proliferative, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Artery, disease
(restenosis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Gastric acid
(secretion, inhibitors; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Shock (circulatory collapse)
(septic, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Spinal column
(spondylitis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Animal tissue
(treatment of tissue degeneration; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Cystic fibrosis
Diabetes insipidus
Psoriasis
Sepsis
**Transplant** rejection
Urticaria
(treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Intestine, disease
(ulcerative colitis, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT Muscle, disease
(wasting, treatment; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT 9036-21-9
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(IV, inhibitors; prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT 306760-71-4P 306760-72-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)
IT 306760-69-0P 306760-86-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT

(Reactant or reagent); USES (Uses)
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)

IT 306759-92-2P 306759-93-3P 306759-94-4P 306759-95-5P 306759-96-6P
306759-97-7P 306759-98-8P 306759-99-9P 306760-00-9P 306760-01-0P
306760-02-1P 306760-03-2P 306760-04-3P 306760-05-4P 306760-06-5P
306760-07-6P 306760-08-7P 306760-09-8P 306760-10-1P 306760-11-2P
306760-12-3P 306760-13-4P 306760-14-5P 306760-15-6P 306760-16-7P
306760-17-8P 306760-18-9P 306760-19-0P 306760-20-3P 306760-21-4P
306760-22-5P 306760-23-6P 306760-24-7P 306760-25-8P 306760-26-9P
306760-27-0P 306760-28-1P 306760-29-2P 306760-30-5P 306760-31-6P
306760-32-7P 306760-33-8P 306760-34-9P 306760-35-0P 306760-36-1P
306760-37-2P 306760-38-3P 306760-39-4P 306760-40-7P 306760-41-8P
306760-42-9P 306760-43-0P 306760-44-1P 306760-45-2P 306760-46-3P
306760-47-4P 306760-48-5P 306760-49-6P 306760-50-9P 306760-51-0P
306760-52-1P 306760-53-2P 306760-54-3P 306760-55-4P 306760-56-5P
306760-57-6P 306760-58-7P 306760-59-8P 306760-60-1P 306760-61-2P
306760-62-3P 306760-63-4P 306760-64-5P 306760-65-6P 306760-66-7P
306760-67-8P 306760-68-9P 306760-70-3P 306760-73-6P 306760-74-7P
306760-75-8P 306760-76-9P 306760-77-0P 306760-78-1P 306760-79-2P
306760-80-5P 306760-81-6P 306760-82-7P 306760-83-8P 306760-84-9P
306760-85-0P 306760-87-2P 306760-88-3P 306760-90-7P 306760-91-8P
306760-92-9P 306760-93-0P 306760-94-1P 306760-95-2P 306760-96-3P
306771-52-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)

IT 64-04-0, Phenethylamine 75-16-1, Methylmagnesium bromide **91-21-4**
, 1,2,3,4-Tetrahydroisoquinoline 100-07-2, 4-Methoxybenzoyl chloride
100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-61-8,
N-Methylaniline, reactions 102-97-6, N-Isopropylbenzylamine 103-49-1,
Dibenzylamine 103-67-3, N-Methylbenzylamine 104-11-0,
N-Methyl-4-chlorobenzylamine 104-63-2, N-Benzylethanolamine 140-75-0,
4-Fluorobenzylamine 403-40-7, 1-(4-Fluorophenyl)ethylamine 403-43-0,
4-Fluorobenzoyl chloride 459-22-3, 4-Fluorophenylacetonitrile
585-32-0, Cumylamine 589-08-2, N-Methylphenethylamine 624-28-2,
2,5-Dibromopyridine 658-93-5, 3,4-Difluorophenylacetic acid 767-00-0,
4-Cyanophenol 874-33-9 917-54-4, Methyllithium 1006-64-0,
2-Phenylpyrrolidine 1194-02-1, 4-Fluorobenzonitrile 1200-27-7
1583-88-6, 2-(4-Fluorophenyl)ethylamine 2627-86-3, (S)-1-
Phenylethylamine 2706-56-1, 2-(2-Aminoethyl)pyridine 2975-41-9,
2-Aminoindane 3082-64-2, (R)-1-Phenylpropylamine 3378-72-1,
N-tert-Butylbenzylamine 3731-51-9, 2-Aminomethylpyridine 3886-69-9,
(R)-1-Phenylethylamine 5933-40-4 5961-59-1, N-Methyl-4-methoxyaniline
6526-79-0 10277-74-4 14321-27-8, N-Ethylbenzylamine 17797-11-4
19131-99-8 20173-04-0 30568-40-2 34698-41-4, 1-Aminoindane
41789-95-1, N-Methyl-3-methoxybenzylamine 52568-28-2 54401-85-3, Ethyl
4-pyridylacetate 61341-86-4 72235-52-0, 2,4-Difluorobenzylamine
74702-89-9 74702-93-5 76532-33-7 127842-54-0, 3,4-
Bis(difluoromethoxy)benzaldehyde 130416-51-2 160001-92-3 194736-72-6
306761-54-6 306761-55-7 306761-56-8 306761-57-9 306761-58-0
306761-59-1 306761-60-4 306761-61-5 306761-62-6 306771-54-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)

IT 17797-10-3P 40377-35-3P 52805-36-4P 90446-25-6P,
4-Difluoromethoxybenzonitrile 93748-09-5P 210530-71-5P 303165-20-0P
303165-21-1P 303165-22-2P 303165-23-3P 306760-97-4P 306760-98-5P
306760-99-6P 306761-00-2P 306761-01-3P 306761-02-4P 306761-03-5P
306761-04-6P 306761-05-7P 306761-06-8P 306761-07-9P 306761-08-0P
306761-09-1P 306761-10-4P 306761-11-5P 306761-12-6P 306761-13-7P
306761-14-8P 306761-15-9P 306761-16-0P, Methyl 2-methyl-2-(3,4-
difluorophenyl)propionate 306761-17-1P 306761-18-2P 306761-19-3P
306761-20-6P 306761-21-7P 306761-22-8P 306761-23-9P 306761-24-0P
306761-25-1P 306761-26-2P 306761-27-3P 306761-28-4P 306761-29-5P
306761-30-8P 306761-31-9P 306761-32-0P 306761-33-1P 306761-34-2P
306761-35-3P 306761-36-4P 306761-37-5P 306761-38-6P 306761-39-7P
306761-40-0P 306761-41-1P 306761-42-2P 306761-43-3P 306761-44-4P

306761-45-5P 306761-46-6P 306761-47-7P 306761-48-8P 306761-49-9P
306761-50-2P 306761-51-3P 306761-52-4P 306761-53-5P 306761-63-7P
306762-34-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyridylethylpyridines as phosphodiesterase 4 inhibitors)

L19 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM C07K005-062
ICS C07K005-065; C07K005-068; C07K005-072; C07K005-078; C07D409-12; A61K038-55; A61P007-02; C07K005-06
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 63
ST amidine guanidine peptidomimetic prepn complement protease inhibitor
IT Respiratory distress syndrome
(adult; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Bronchi
(chronic bronchitis; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Nervous system
(disease; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Reperfusion
(injury; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Pancreas, disease
(pancreatitis; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Alzheimer's disease
Anaphylaxis
Asthma
Autoimmune disease
Enzyme kinetics
Kidney, disease
Peptidomimetics
Rheumatoid arthritis
Sepsis
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Rheumatic diseases
(rheumatoid disease; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Abortion
(spontaneous; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Lupus erythematosus
(systemic; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Thyroid gland, disease
(thyroiditis; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Injury
(trauma, thermal; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Intestine, disease
(ulcerative colitis; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT Blood vessel, disease
(vasculitis; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT **Transplant** rejection
(xeno-; prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)
IT 181130-23-4 182159-04-2 182159-10-0 203792-61-4 203792-65-8
203792-72-7 203792-90-9 301192-62-1 301192-64-3 301192-65-4
301192-67-6 301192-69-8 301192-71-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

IT 232282-24-5P 232282-27-8P 232612-52-1P 232612-59-8P 301188-17-0P
301188-45-4P 301188-47-6P 301188-48-7P 301188-49-8P 301188-50-1P
301188-52-3P 301188-53-4P 301188-55-6P 301188-57-8P 301188-59-0P
301188-60-3P 301188-61-4P 301188-63-6P 301188-64-7P 301188-66-9P
301188-68-1P 301188-70-5P 301188-72-7P 301188-74-9P 301188-75-0P
301188-79-4P 301188-81-8P 301188-82-9P 301188-83-0P 301188-84-1P
301188-85-2P 301188-86-3P 301188-88-5P 301188-90-9P 301188-92-1P
301188-94-3P 301188-95-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

IT 96-32-2, Bromoacetic acid, methyl ester 611-95-0 **1120-71-4**
1197-18-8 1694-92-4 1755-15-3, 2-Acetyldimedone 4025-75-6,
4-Nitrobenzylsulfonyl chloride 7146-15-8 14328-64-4 16473-35-1
23903-46-0 29022-11-5, Fmoc-gly-oh 29640-13-9 35661-39-3
40724-47-8 50667-66-8 55406-13-8 57699-45-3 70491-05-3
71989-31-6 82835-61-8 104366-23-6 108052-76-2 121099-13-6
124789-19-1 126062-63-3 144644-00-8 186145-08-4 203792-23-8
232280-85-2 300363-81-9 301188-02-3 301188-03-4 301188-04-5
301188-06-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

IT 21512-20-9P 232281-11-7P 232281-12-8P 232281-13-9P 232281-14-0P
232281-15-1P 232281-16-2P 232281-17-3P 232281-18-4P 232281-19-5P
232281-20-8P 232281-21-9P 232281-22-0P 232281-23-1P 300363-82-0P
300363-83-1P 301188-05-6P 301188-07-8P 301188-08-9P 301188-09-0P
301188-10-3P 301188-11-4P 301188-12-5P 301188-13-6P 301188-14-7P
301188-15-8P 301188-18-1P 301188-19-2P 301188-20-5P 301188-21-6P
301188-22-7P 301188-24-9P 301188-25-0P 301188-26-1P 301188-27-2P
301188-28-3P 301188-29-4P 301188-30-7P 301188-31-8P 301188-32-9P
301188-33-0P 301188-34-1P 301188-35-2P 301188-36-3P 301188-37-4P
301188-38-5DP, resin-bound 301188-39-6DP, resin-bound 301188-40-9DP, resin-bound 301188-41-0DP, resin-bound 301188-42-1DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

IT 232280-81-8P 232280-83-0P 232282-03-0P 301188-43-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

IT 301188-76-1P 301188-77-2P 301188-96-5P 301188-97-6P 301188-98-7P
301188-99-8P 301189-00-4P 301189-01-5P 301189-02-6P 301189-04-8P
301189-05-9P 301189-06-0P 301189-08-2P 301189-10-6P 301189-11-7P
301189-12-8P 301189-13-9P 301189-14-0P 301189-15-1P 301189-16-2P
301189-17-3P 301189-18-4P 301189-19-5P 301189-20-8P 301189-21-9P
301189-22-0P 301189-23-1P 301189-24-2P 301189-25-3P 301189-26-4P
301189-27-5P 301189-28-6P 301189-29-7P 301189-30-0P 301189-31-1P
301189-32-2P 301189-33-3P 301189-34-4P 301189-35-5P 301189-36-6P
301189-37-7P 301189-38-8P 301189-39-9P 301189-40-2P 301189-41-3P
301189-42-4P 301189-43-5P 301189-44-6P 301189-45-7P 301189-46-8P
301189-47-9P 301189-48-0P 301189-49-1P 301189-50-4P 301189-51-5P
301189-52-6P 301189-53-7P 301189-54-8P 301189-55-9P 301189-56-0P
301189-57-1P 301189-58-2P 301189-59-3P 301189-60-6P 301189-61-7P
301189-62-8P 301189-63-9P 301189-64-0P 301189-65-1P 301189-66-2P
301189-67-3P 301189-68-4P 301189-69-5P 301189-70-8P 301189-71-9P
301189-72-0P 301189-73-1P 301189-74-2P 301189-75-3P 301189-76-4P
301189-77-5P 301189-78-6P 301189-79-7P 301189-80-0P 301189-81-1P
301189-82-2P 301189-83-3P 301189-84-4P 301189-85-5P 301189-86-6P
301189-87-7P 301189-88-8P 301189-89-9P 301189-90-2P 301189-91-3P

301189-92-4P 301189-93-5P 301189-94-6P 301189-95-7P 301189-96-8P
301189-97-9P 301189-98-0P 301189-99-1P 301190-00-1P 301190-01-2P
301190-02-3P 301190-03-4P 301190-04-5P 301190-06-7P 301190-07-8P
301190-08-9P 301190-09-0P 301190-10-3P 301190-11-4P 301190-12-5P
301190-13-6P 301190-14-7P 301190-15-8P 301190-16-9P 301190-17-0P
301190-18-1P 301190-19-2P 301190-20-5P 301190-21-6P 301190-22-7P
301190-23-8P 301190-24-9P 301190-25-0P 301190-26-1P 301190-27-2P
301190-28-3P 301190-29-4P 301190-30-7P 301190-31-8P 301190-32-9P
301190-33-0P 301190-34-1P 301190-35-2P 301190-36-3P 301190-37-4P
301190-38-5P 301190-39-6P 301190-40-9P 301190-41-0P 301190-42-1P
301190-43-2P 301190-44-3P 301190-45-4P 301190-46-5P 301190-47-6P
301190-48-7P 301190-49-8P 301190-50-1P 301190-51-2P 301190-52-3P
301190-53-4P 301190-54-5P 301190-55-6P 301190-56-7P 301190-57-8P
301190-58-9P 301190-59-0P 301190-60-3P 301190-61-4P 301190-62-5P
301190-63-6P 301190-64-7P 301190-65-8P 301190-66-9P 301190-67-0P
301190-68-1P 301190-69-2P 301190-70-5P 301190-71-6P 301190-72-7P
301190-73-8P 301190-74-9P 301190-75-0P 301190-76-1P 301190-77-2P
301190-78-3P 301190-79-4P 301190-80-7P 301190-81-8P 301190-82-9P
301190-83-0P 301190-84-1P 301190-85-2P 301190-86-3P 301190-87-4P
301190-88-5P 301190-89-6P 301190-90-9P 301190-91-0P 301190-92-1P
301190-93-2P 301190-94-3P 301190-95-4P 301190-96-5P 301190-97-6P
301190-98-7P 301190-99-8P 301191-00-4P 301191-01-5P 301191-02-6P
301191-03-7P 301191-04-8P 301191-05-9P 301191-06-0P 301191-07-1P
301191-08-2P 301191-09-3P 301191-10-6P 301191-11-7P 301191-12-8P
301191-13-9P 301191-14-0P 301191-15-1P 301191-16-2P 301191-17-3P
301191-18-4P 301191-19-5P 301191-20-8P 301191-21-9P 301191-22-0P
301191-23-1P 301191-25-3P 301191-26-4P 301191-28-6P 301191-30-0P
301191-32-2P 301191-33-3P 301191-34-4P 301191-36-6P 301191-37-7P
301191-39-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

IT 301191-41-3P 301191-42-4P 301191-43-5P 301191-44-6P 301191-45-7P
301191-46-8P 301191-48-0P 301191-49-1P 301191-50-4P 301191-51-5P
301191-52-6P 301191-53-7P 301191-54-8P 301191-55-9P 301191-56-0P
301191-57-1P 301191-58-2P 301191-59-3P 301191-60-6P 301191-61-7P
301191-62-8P 301191-63-9P 301191-64-0P 301191-65-1P 301191-67-3P
301191-68-4P 301191-69-5P 301191-71-9P 301191-72-0P 301191-73-1P
301191-74-2P 301191-75-3P 301191-76-4P 301191-77-5P 301191-78-6P
301191-79-7P 301191-80-0P 301191-81-1P 301191-82-2P 301191-83-3P
301191-84-4P 301191-85-5P 301191-86-6P 301191-87-7P 301191-88-8P
301191-89-9P 301191-90-2P 301191-91-3P 301191-92-4P 301191-94-6P
301191-95-7P 301191-96-8P 301191-97-9P 301191-98-0P 301191-99-1P
301192-00-7P 301192-01-8P 301192-02-9P 301192-03-0P 301192-04-1P
301192-05-2P 301192-06-3P 301192-07-4P 301192-08-5P 301192-09-6P
301192-10-9P 301192-11-0P 301192-12-1P 301192-13-2P 301192-14-3P
301192-15-4P 301192-16-5P 301192-17-6P 301192-18-7P 301192-19-8P
301192-20-1P 301192-21-2P 301192-22-3P 301192-23-4P 301192-24-5P
301192-25-6P 301192-26-7P 301192-27-8P 301192-28-9P 301192-30-3P
301192-31-4P 301192-32-5P 301192-33-6P 301192-34-7P 301192-35-8P
301192-36-9P 301192-37-0P 301192-38-1P 301192-39-2P 301192-40-5P
301192-41-6P 301192-42-7P 301192-43-8P 301192-44-9P 301192-45-0P
301192-46-1P 301192-47-2P 301192-48-3P 301192-49-4P 301192-50-7P
301192-51-8P 301192-52-9P 301192-53-0P 301192-54-1P 301192-55-2P
301192-56-3P 301192-57-4P 301192-58-5P 301192-59-6P 301192-60-9P
301192-61-0P 301200-36-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amidine- or guanidine-contg. peptidomimetics for use as inhibitors of complement proteases)

L19 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM C07D211-14
ICS A61K031-445; A61K031-47; A61K031-495; C07D211-52; C07D211-58; C07D211-74; C07D295-14; C07D401-06; C07D405-06
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 28

ST piperidine prepn neurokinin antagonist treatment disease; NK1 NK2 receptor antagonist piperidine prepn

IT Tachykinin receptors
(NK1 antagonists; prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT Tachykinin receptors
(NK2 antagonists; prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT Eye
(conjunctiva; prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT Digestive tract
(disease; prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT Anti-inflammatory agents
(nonsteroidal; prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT Allergy inhibitors
Analgesics
Anti-Alzheimer's agents
Antiasthmatics
Antitussives
Autoimmune disease
Cardiovascular agents
Down's syndrome
Eye, disease
Multiple sclerosis
Psychotropics
**Transplant** rejection
(prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT Lupus erythematosus
(systemic; prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT 181879-21-0P 186310-47-4P 186446-71-9P 186446-72-0P 186446-73-1P
186446-74-2P 186446-75-3P 186446-76-4P 186446-77-5P 186446-78-6P
186446-79-7P 186446-80-0P 186446-81-1P 186446-82-2P 186446-83-3P
186446-84-4P 186446-85-5P 186446-86-6P 186446-87-7P 186446-88-8P
186446-89-9P 186446-90-2P 186446-91-3P 186446-92-4P 186446-93-5P
186446-94-6P 186446-97-9P 186446-98-0P 186446-99-1P 186447-00-7P
186447-01-8P 186447-02-9P 186447-03-0P 186447-04-1P 186447-05-2P
186447-06-3P 186447-07-4P 186447-08-5P 186447-09-6P 186447-77-8P
186447-79-0P 186447-80-3P 214475-81-7P 214475-82-8P 214475-84-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT 90-04-0, o-Anisidine **91-21-4**, 1,2,3,4-Tetrahydroisoquinoline
100-61-8, reactions 103-67-3 106-47-8, 4-Chloroaniline, reactions
120-57-0, Piperonal 120-72-9, Indole, reactions 141-97-9, Ethyl acetoacetate 328-74-5, 3,5-Bis(trifluoromethyl)aniline 589-08-2, N-Methylphenethylamine 635-46-1, 1,2,3,4-Tetrahydroquinoline 932-96-7, 4-Chloro-N-methylaniline 2759-28-6, N-Phenylmethylpiperazine
4165-96-2, 3-Phenylglutaric acid 5004-94-4 5961-59-1, 4-Methoxy-N-methylaniline 6287-38-3, 3,4-Dichlorobenzaldehyde
6851-80-5 21364-46-5, Isoquinoline hydrochloride 31252-42-3, 4-Benzylpiperidine 34036-07-2, 3,4-Difluorobenzaldehyde 40807-61-2, 4-Phenyl-4-hydroxypiperidine 41789-95-1 41979-39-9, 4-Piperidone hydrochloride 77775-71-4 85068-29-7, 3,5-Bis(trifluoromethyl)benzylamine 136076-91-0 142001-86-3, 4-Acetylamino-4-phenylpiperidine hydrochloride 186447-76-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of piperidines as neurokinin antagonists for treatment of diseases)

IT 4160-80-9P, 3-Phenylglutaric anhydride 4759-64-2P 103860-25-9P

103982-67-8P 110145-81-8P 158471-13-7P 181880-45-5P 186310-58-7P
186310-59-8P 186310-60-1P 186447-10-9P 186447-11-0P 186447-12-1P
186447-13-2P 186447-14-3P 186447-15-4P 186447-16-5P 186447-17-6P
186447-18-7P 186447-19-8P, 3-(3,4-Difluorophenyl)glutaric acid
186447-20-1P, 3-(3,4-Difluorophenyl)glutaric anhydride 186447-21-2P
186447-22-3P 186447-23-4P 186447-24-5P 186447-25-6P 186447-27-8P
186447-28-9P 186447-29-0P 186447-30-3P 186447-31-4P 186447-32-5P
186447-33-6P 186447-34-7P 186447-35-8P 186447-36-9P 186447-37-0P
186447-38-1P 186447-39-2P 186447-40-5P 186447-41-6P 186447-42-7P
186447-43-8P 186447-44-9P 186447-45-0P 186447-46-1P 186447-47-2P
186447-48-3P 186447-49-4P 186447-50-7P 186447-51-8P 186447-52-9P
186447-53-0P 186447-54-1P 186447-55-2P 186447-56-3P 186447-57-4P
186447-58-5P 186447-59-6P 186447-60-9P 186447-61-0P 186447-62-1P
186447-63-2P 186447-64-3P 186447-65-4P 186447-66-5P 186447-67-6P
186447-69-8P 186447-70-1P 186447-71-2P 186447-72-3P 186447-73-4P
186447-74-5P 186447-81-4P 186447-82-5P 214475-79-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperidines as neurokinin antagonists for treatment of diseases)

L19 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM C07D215-58
ICS A61K031-435; A61K031-495; A61K031-40; A61K031-415; C07D209-08; C07D217-06; C07D217-08; C07D237-32
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
ST benzenesulfonylheterocycle prepn phosphodiesterase IV inhibitor; tumor necrosis factor inhibitor benzenesulfonylheterocycle; quinoline benzenesulfonyl prepn drug; indoline benzenesulfonyl prepn drug; isatin benzenesulfonyl prepn drug; gastroprotectant benzenesulfonylheterocycle
IT Intestine, disease
(Crohn's, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Respiratory distress syndrome
(acute, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Respiratory distress syndrome
(adult, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Eye, disease
(allergic conjunctivitis, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Nose
(allergic rhinitis, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT **Transplant** and **Transplantation**
(allotransplant, treatment of allograft rejection; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Heart, disease
(arrest, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Dermatitis
Dermatitis
(atopic, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Bronchi

(bronchitis, treatment of chronic bronchitis; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Malaria
Malaria
(cerebral, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Kidney, disease
(chronic glomerulonephritis, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Lung, disease
Lung, disease
(chronic inflammation, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Movement disorders
(claudication, treatment of intermittant claudication; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Mental disorder
(dementia, multi-infarct, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Aging, animal
(disorder, senility, treatment of cerebral senility; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Granuloma
Granuloma
(eosinophilic, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT **Transplant** and **Transplantation**
(graft-vs.-host reaction, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Joint, anatomical
(inflammation, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Intestine, disease
(inflammatory, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(inhibitors; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Reperfusion
(injury, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Antitumor agents
(leukemia; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Brain, disease
Brain, disease
(malaria, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Muscle, disease
(myalgia, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Kidney, disease
(nephritis, treatment of anaphylactoid purpura nephritis; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Antiasthmatics
Antidepressants
Antidiabetic agents
Antipyretics
Fungicides
(prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Bone
(resorption, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Mental disorder
(senile psychosis, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Aging, animal
(senility, treatment of cerebral senility; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Shock (circulatory collapse)
(septic, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Brain, disease
(stroke, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Lupus erythematosus
(systemic, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Nervous system
(tardive dyskinesia, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Shock (circulatory collapse)
(toxic shock syndrome, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Eye
(treatment of eye inflammation and allergy; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Parkinson's disease
(treatment of memory impairment assocd. with Parkinson's disease; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)
IT Eosinophil

(treatment of pathol. conditions; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT AIDS (disease)
Antiarthritics
Autoimmune disease
Cachexia
Diabetes insipidus
Influenza
Keloid
Keratosis
Malaria
Multiple sclerosis
Osteoarthritis
Psoriasis
Rheumatoid arthritis
Septicemia
Silicosis
Urticaria
(treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Intestine, disease
(ulcerative colitis, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT Eye, disease
(vernal conjunctivitis, treatment; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT 9036-21-9, Phosphodiesterase IV
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(inhibitors; prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT 185243-74-7P 185243-76-9P 185243-81-6P 185243-85-0P 185243-89-4P
185243-94-1P 185243-99-6P 185244-03-5P 185244-06-8P 185244-09-1P
185244-11-5P 185244-12-6P 185244-14-8P 185244-15-9P 185244-16-0P
185244-17-1P 185244-18-2P 185244-19-3P 185244-20-6P 185244-21-7P
185244-22-8P 185244-23-9P 185244-24-0P 185244-25-1P 185244-26-2P
185244-27-3P 185244-28-4P 185244-29-5P 185244-30-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT 88-67-5, 2-Iodobenzoic acid 90-05-1, 2-Methoxyphenol **91-21-4**,
1,2,3,4-Tetrahydroisoquinoline 119-39-1, 1(2H)-Phthalazinone 496-15-1,
Indoline 588-63-6, 3-Phenoxypropyl bromide 771-50-6,
Indole-3-carboxylic acid 835-18-7 1022-45-3 1945-84-2,
2-Ethynylpyridine 7115-13-1, 3-Phenylisocarbostyril 23095-31-0
23441-75-0 24365-65-9 35969-62-1 36828-24-7, 4-Phenylisocarbostyril
67123-97-1, 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid 69454-42-8
78318-00-0 127168-82-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins, and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

IT 942-24-5P, 3-Methoxycarbonylindole 57060-86-3P 63624-27-1P
98910-57-7P 185244-31-9P 185244-32-0P 185244-33-1P 185244-34-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzenesulfonyltetrahydroquinolines, -indolines, -isatins,

and related compds. as inhibitors of phosphodiesterase IV and tumor necrosis factor)

L19 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
CC 63-7 (Pharmaceuticals)
ST polyethylene oxide sulfonated anticalcification bioprosthetic
IT Calcification
(anticalcification treatment of biol. tissues by grafting of sulfonated polyethylene oxide)
IT **Transplant** and **Transplantation**
(heart valve; anticalcification treatment of biol. tissues by grafting of sulfonated polyethylene oxide)
IT Heart
(valve, bioprosthetic; anticalcification treatment of biol. tissues by grafting of sulfonated polyethylene oxide)
IT **1120-71-4D**, Propanesultone, reaction products with PEG
32130-27-1D, sulfonated
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(anticalcification treatment of biol. tissues by grafting of sulfonated polyethylene oxide)

L19 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM A61K031-52
ICS A61K031-00
CC 1-10 (Pharmacology)
ST xanthine deriv tissue injury hypoxia; heterocyclylalkylamine shock treatment
IT Diabetes mellitus
(acidosis in; method and agents for preventing tissue injury from hypoxia)
IT Neutrophil
(adherence and chemotaxis by, lisofylline effect on)
IT Azines
Flavins
Lactams
Lactones
Polyoxadiazoles
Polyquinoxalines
Sultams
Sultines
Sultones
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl derivs.; method and agents for preventing tissue injury from hypoxia)
IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl; method and agents for preventing tissue injury from hypoxia)
IT Chemotaxis
(by neutrophil, lisofylline effect on; method and agents for preventing tissue injury from hypoxia)
IT Amines, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclyl; method and agents for preventing tissue injury from hypoxia)
IT Signal transduction, biological
(inhibitors; method and agents for preventing tissue injury from hypoxia)
IT Phosphatidic acids
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(linoleic acid-contg.; method and agents for preventing tissue injury from hypoxia)
IT Acidosis
Burn
Cystic fibrosis
Hypoxia
Parkinsonism
(method and agents for preventing tissue injury from hypoxia)
IT **Transplant** and **Transplantation**
(organ dysfunction after; method and agents for preventing tissue injury from hypoxia)
IT Sepsis and Septicemia
(shock from; method and agents for preventing tissue injury from hypoxia)
IT Blood vessel
(surgery on; method and agents for preventing tissue injury from hypoxia)
IT Respiratory distress syndrome
(acute, method and agents for preventing tissue injury from hypoxia)
IT Artery
(angioplasty, peripheral; method and agents for preventing tissue injury from hypoxia)
IT Adhesion
(bio-, by neutrophil, lisofylline effect on; method and agents for preventing tissue injury from hypoxia)
IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclazines, aza analogs, aminoalkyl derivs.; method and agents for preventing tissue injury from hypoxia)
IT Nerve, disease
(degeneration, method and agents for preventing tissue injury from hypoxia)
IT Acidosis
(diabetic, method and agents for preventing tissue injury from hypoxia)
IT Nervous system
(disease, Huntington's chorea, method and agents for preventing tissue injury from hypoxia)
IT Nervous system
(disease, amyotrophic lateral sclerosis, method and agents for preventing tissue injury from hypoxia)
IT Animal tissue
(disease, injury, method and agents for preventing tissue injury from hypoxia)
IT Organ
(disease, multiorgan dysfunction, method and agents for preventing tissue injury from hypoxia)
IT Lung, disease
(edema, high-altitude; method and agents for preventing tissue injury from hypoxia)
IT Heart, disease
(failure, method and agents for preventing tissue injury from hypoxia)
IT Shock
(hemorrhagic, method and agents for preventing tissue injury from hypoxia)
IT Atmosphere, environmental
Stress, biological
(high-altitude, method and agents for preventing tissue injury from hypoxia)
IT Heart, disease
(infarction, method and agents for preventing tissue injury from hypoxia)
IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(nitrogen, perhydroazolopyridines, aminoalkyl derivs.; method and agents for preventing tissue injury from hypoxia)

IT Acidosis
(renal tubular, method and agents for preventing tissue injury from hypoxia)

IT Shock
(septic, method and agents for preventing tissue injury from hypoxia)

IT Brain, disease
(stroke, method and agents for preventing tissue injury from hypoxia)

IT Meso-ionic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sydnones, aminoalkyl derivs.; method and agents for preventing tissue injury from hypoxia)

IT Heart
Intestine
Kidney
Liver
Lung
(**transplant**, organ dysfunction after; method and agents for preventing tissue injury from hypoxia)

IT Lymphokines and Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tumor necrosis factor-.alpha., method and agents for preventing tissue injury from hypoxia)

IT Surgery
(vascular, method and agents for preventing tissue injury from hypoxia)

IT Interferons
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.gamma., method and agents for preventing tissue injury from hypoxia)

IT 493-09-4D, aminoalkyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzomethod and agents for preventing tissue injury from hypoxia)

IT 50-71-5D, Alloxan, aminoalkyl derivs. 50-81-7D, Ascorbic acid, aminoalkyl derivs. 51-17-2D, Benzimidazole, aminoalkyl derivs. 58-63-9D, Inosine, aminoalkyl derivs. 58-85-5D, Biotin, aminoalkyl derivs. 59-48-3D, Oxindole, aminoalkyl derivs. 59-49-4D, 2(3H)-Benzoxazolone, aminoalkyl derivs. 65-71-4D, Thymine, aminoalkyl derivs. 65-86-1D, Orotic acid, aminoalkyl derivs. 66-22-8D, Uracil, aminoalkyl derivs. 67-52-7D, Barbituric acid, aminoalkyl derivs. 69-89-6D, Xanthine, derivs. 73-24-5D, Adenine, aminoalkyl derivs. 73-40-5D, Guanine, aminoalkyl derivs. 81-88-9D, aminoalkyl derivs. 84-11-7D, Phenanthraquinone, aminoalkyl derivs. 84-65-1D, Anthraquinone, aminoalkyl derivs. 85-41-6D, Phthalimide, aminoalkyl derivs. 85-44-9D, 1,3-Isobenzofurandione, aminoalkyl derivs. 86-74-8D, Carbazole, aminoalkyl derivs. 87-41-2D, Phthalide, isoquinoline derivs., aminoalkyl 87-99-0D, Xylitol, aminoalkyl derivs. 90-46-0D, Xanthydrol, aminoalkyl derivs. 90-47-1D, Xanthone, aminoalkyl derivs. 91-18-9D, Pteridine, aminoalkyl derivs. 91-19-0D, Quinoxaline, aminoalkyl derivs. 91-20-3D, Naphthalene, aminoalkyl derivs. **91-21-4D**, aminoalkyl derivs. 91-22-5D, Quinoline, aminoalkyl derivs. 91-22-5D, Quinoline, aminoalkyl oxo derivs. 91-22-5D, Quinoline, furano derivs., aminoalkyl 91-56-5D, Isatin, aminoalkyl derivs. 91-64-5D, Coumarin, aminoalkyl derivs. 92-82-0D, Phenazine, aminoalkyl derivs. 92-83-1D, Xanthene, aminoalkyl derivs. 92-84-2D, Phenothiazine, aminoalkyl derivs. 95-14-7D, 1H-Benzotriazole, aminoalkyl derivs. 95-15-8D, Benzothiophene, aminoalkyl derivs. 95-15-8D, Thianaphthene, aminoalkyl derivs. 95-16-9D, Benzothiazole, aminoalkyl derivs. 96-48-0D, Butyrolactone, aminoalkyl derivs. 100-76-5D, Quinuclidine, aminoalkyl derivs. 105-60-2D, Caprolactam, aminoalkyl derivs. 109-97-7D, Azole, aminoalkyl and azino derivs. 109-97-7D, Pyrrole, aminoalkyl azino derivs.

109-97-7D, Pyrrole, aminoalkyl derivs. 109-99-9D, Tetrahydrofuran, aminoalkyl derivs. 110-00-9D, Furan, aminoalkyl derivs. 110-01-0D, Tetrahydrothiophene, aminoalkyl derivs. 110-02-1D, Thiophene, aminoalkyl derivs. 110-85-0D, Piperazine, aminoalkyl dioxo derivs. 110-86-1D, Pyridine, alkyl aminoalkyl derivs. 110-86-1D, Pyridine, aminoalkyl derivs. 110-88-3D, Trioxane, aminoalkyl derivs. 110-89-4D, Piperidine, aminoalkyl derivs. 110-91-8D, Morpholine, aminoalkyl derivs. 118-92-3D, Anthranilic acid, aminoalkyl derivs. 119-65-3D, Isoquinoline, aminoalkyl derivs. 119-65-3D, Isoquinoline, phthalide derivs., aminoalkyl 120-72-9D, Indole, aminoalkyl azino derivs. 120-73-0D, Purine, aminoalkyl derivs. 123-56-8D, Succinimide, aminoalkyl derivs. 123-75-1D, Pyrrolidine, aminoalkyl derivs. 123-91-1D, Dioxane, aminoalkyl derivs. 126-33-0D, Sulfolane, aminoalkyl derivs. 132-64-9D, Dibenzofuran, aminoalkyl derivs. 132-65-0D, Dibenzothiophene, aminoalkyl derivs. 135-67-1D, Phenoxazine, aminoalkyl derivs. 142-68-7D, Tetrahydropyran, aminoalkyl derivs. 147-85-3D, Proline, aminoalkyl derivs. 204-02-4D, Perimidine, aminoalkyl derivs. 229-87-8D, Phenanthridine, aminoalkyl derivs. 230-17-1D, Benzo[c]cinnoline, aminoalkyl derivs. 243-82-3D, Benzo[f]pyrido[1,2-a]indole, aminoalkyl dioxo derivs. 251-59-2D, 1H-Pyrrolizine, aminoalkyl derivs. 253-52-1D, Phthalazine, aminoalkyl derivs. 253-66-7D, Cinnoline, aminoalkyl derivs. 253-82-7D, Quinazoline, aminoalkyl derivs. 254-04-6D, Benzopyran, aminoalkyl derivs. 254-04-6D, 3-Chromene, oxopyrano derivs., aminoalkyl 254-18-2D, Benzoxazine, aminoalkyl derivs. 254-37-5D, 2H-1-Benzothiopyran, aminoalkyl derivs. 254-45-5D, 2H-1,3-Benzothiazine, aminoalkyl derivs. 255-58-3D, 2H-Quinolizine, aminoalkyl derivs. 256-96-2D, 5H-Dibenz[b,f]azepine, aminoalkyl derivs. 258-72-0D, Triphenodioxazine, aminoalkyl derivs. 258-74-2D, Triphenodithiazine, aminoalkyl derivs. 260-94-6D, Acridine, aminoalkyl derivs. 262-20-4D, Phenoxathiin, aminoalkyl derivs. 270-68-8D, Isoindole, aminoalkyl derivs. 270-75-7D, Isobenzofuran, aminoalkyl derivs. 271-89-6D, Benzofuran, aminoalkyl derivs. 271-95-4D, 1,2-Benzisoxazole, aminoalkyl derivs. 272-16-2D, 1,2-Benzisothiazole, aminoalkyl derivs. 273-53-0D, Benzoxazole, aminoalkyl derivs. 274-09-9D, 1,3-Benzodioxole, aminoalkyl derivs. 274-40-8D, Indolizine, aminoalkyl derivs. 280-38-6D, Isoquinuclidine, aminoalkyl derivs. 288-13-1D, Pyrazole, aminoalkyl derivs. 288-14-2D, Isoxazole, aminoalkyl and oxo derivs. 288-16-4D, Isothiazole, aminoalkyl derivs. 288-32-4D, Imidazole, aminoalkyl derivs. 288-37-9D, Furazan, aminoalkyl derivs. 288-42-6D, Oxazole, aminoalkyl derivs. 288-47-1D, Thiazole, aminoalkyl derivs. 288-74-4D, 1,3-Dithiole, aminoalkyl derivs. 288-96-0D, 1,2,3,5-Thiatriazole, aminoalkyl derivs. 289-06-5D, Thiadiazole, aminoalkyl derivs. 289-19-0D, Pentazole, aminoalkyl derivs. 289-80-5D, Pyridazine, aminoalkyl and oxo derivs. 289-95-2D, Pyrimidine, aminoalkyl derivs. 290-37-9D, Pyrazine, aminoalkyl derivs. 290-97-1D, Pentazine, aminoalkyl derivs. 291-21-4D, 1,3,5-Trithiane, aminoalkyl derivs. 291-70-3D, Oxepin, aminoalkyl derivs. 291-72-5D, Thiepin, aminoalkyl derivs. 293-30-1D, Tetraoxane, aminoalkyl derivs. 461-72-3D, Hydantoin, aminoalkyl derivs. 480-96-6D, Benzofuroxan, aminoalkyl derivs. 487-21-8D, Lumazine, aminoalkyl derivs. 490-59-5D, Alloxazine, aminoalkyl derivs. 491-38-3D, Chromone, pyrano derivs., aminoalkyl 493-05-0D, Isochroman, aminoalkyl derivs. 493-08-3D, Chroman, furano derivs., aminoalkyl 493-10-7D, Quinolizidine, aminoalkyl derivs. 494-12-2D, Flavan, aminoalkyl derivs. 496-12-8D, Isoindoline, aminoalkyl derivs. 497-23-4D, 2(5H)-Furanone, aminoalkyl derivs. 497-25-6D, 2-Oxazolidinone, aminoalkyl derivs. 497-27-8D, Furoxan, aminoalkyl derivs. 503-86-6D, Glycocyamidine, aminoalkyl derivs. 504-70-1D, Pyrazolidine, aminoalkyl derivs. 504-72-3D, Isoxazolidine, aminoalkyl derivs. 504-73-4D, Isoxazoline, aminoalkyl and oxo derivs. 504-76-7D, Oxazolidine, aminoalkyl derivs. 504-78-9D, Tetrahydrothiazole, aminoalkyl derivs. 505-19-1D, Hexahydropyridazine, aminoalkyl derivs. 525-82-6D, Flavone, aminoalkyl derivs. 529-17-9D, Tropane, aminoalkyl derivs. 541-59-3D, Maleimide, aminoalkyl derivs. 543-75-9D, Dioxene, aminoalkyl derivs. 574-12-9D, Isoflavone, aminoalkyl derivs. 578-95-0D, Acridone, aminoalkyl derivs. 596-24-7D, Fluoran, aminoalkyl derivs. 643-20-9D, Pyrrolizidine, aminoalkyl derivs. 646-06-0D, Dioxolane, aminoalkyl and oxo derivs. 673-66-5D, Enantholactam,

aminoalkyl derivs. 1047-16-1D, Quinacridone, aminoalkyl derivs. 1072-72-6D, aminoalkyl derivs. 1075-14-5D, Thiocoumarin, aminoalkyl derivs. 1613-51-0D, Tetrahydrothiapyran, aminoalkyl derivs. 1904-65-0D, aminoalkyl derivs. 1916-63-8D, Phenoxazone, aminoalkyl derivs. 2051-28-7D, Decahydroquinoline, aminoalkyl derivs. 2054-35-5D, Thiachroman, aminoalkyl derivs. 2236-60-4D, Pterin, aminoalkyl derivs. 2321-07-5D, Fluorescein, aminoalkyl derivs. 3986-98-9D, Thiocoumarin, aminoalkyl derivs. 4375-14-8D, Perhydroindole, aminoalkyl derivs. 4388-04-9D, Dichromylene, aminoalkyl derivs. 4702-34-5D, aminoalkyl derivs. 4829-04-3D, Dithiolane, aminoalkyl derivs. 5666-38-6D, 5(4H)-Thiazolone, aminoalkyl derivs. 5814-98-2D, Isatogen, aminoalkyl derivs. 11084-05-2D, Oxazine, aminoalkyl oxo derivs. 11084-06-3D, Thiazine, aminoalkyl derivs. 11116-90-8D, Dithiole, aminoalkyl derivs. 11120-54-0D, Oxadiazole, aminoalkyl derivs. 12041-95-1D, Benzacridine, aminoalkyl derivs. 12654-97-6D, Triazine, aminoalkyl derivs. 12678-01-2D, Phenanthroline, aminoalkyl derivs. 12688-68-5D, Diazepine, aminoalkyl derivs. 12764-48-6D, Azepine, aminoalkyl derivs. 12766-00-6D, Quinazolinone, aminoalkyl derivs. 12770-99-9D, Dibenzoxazepine, aminoalkyl derivs. 13618-93-4D, Indolizidine, aminoalkyl derivs. 15646-46-5D, Oxazolone, aminoalkyl derivs. 25002-56-6D, Pyridocoline, aminoalkyl derivs. 25512-65-6D, aminoalkyl derivs. 27154-43-4D, Piperidone, aminoalkyl derivs. 27790-74-5D, Dihydropyrimidine, aminoalkyl derivs. 27790-75-6D, Dihydropyridine, aminoalkyl derivs. 27942-00-3D, Methyluracil, aminoalkyl derivs. 27988-97-2D, Tetrazole, aminoalkyl derivs. 28299-33-4D, aminoalkyl derivs. 28452-93-9D, aminoalkyl derivs. 28600-65-9D, Thiazolidinone, aminoalkyl derivs. 29100-30-9D, Thiadecalin, aminoalkyl derivs. 29468-20-0D, Pyridinethione, aminoalkyl derivs. 29990-68-9D, Piperazinedione, aminoalkyl derivs. 30969-75-6D, aminoalkyl derivs. 30969-75-6D, Oxazoline, aminoalkyl oxo derivs. 31152-37-1D, Thiazoline, aminoalkyl derivs. 33941-07-0D, Pyran, aminoalkyl derivs. 33941-07-0D, Pyran, furo derivs., aminoalkyl 36312-17-1D, Dihydrofuran, aminoalkyl derivs. 37275-48-2D, Bipyridine, aminoalkyl derivs. 37294-42-1D, Imidazoquinazoline, aminoalkyl derivs. 37306-44-8D, Triazole, aminoalkyl and dihydro and oxo derivs. 39327-16-7D, Benzoquinoline, aminoalkyl derivs. 39372-88-8D, Dioxepin, aminoalkyl derivs. 43135-91-7D, Benzimidazolone, aminoalkyl derivs. 47420-28-0D, Trixolane, aminoalkyl derivs. 51289-96-4D, Polyoxadiazole, aminoalkyl derivs. 51434-75-4D, Dithiazole, aminoalkyl derivs. 51667-26-6D, Oxazolidinone, aminoalkyl derivs. 52623-09-3D, Phthalone, aminoalkyl derivs. 57917-36-9D, Oxathiane, aminoalkyl derivs. 58536-70-2D, 2H-Benzimidazole-2-thione, aminoalkyl derivs. 59052-72-1D, Pyrimidinethione, aminoalkyl derivs. 60451-06-1D, Benzopyrone, aminoalkyl derivs. 60475-00-5D, Thiopyran, aminoalkyl and oxo derivs. 61215-72-3D, Tetrahydropyridine, aminoalkyl derivs. 61536-83-2D, Benzothiepin, aminoalkyl derivs. 63863-32-1D, aminoalkyl derivs. 64083-16-5D, Naphthofuran, aminoalkyl derivs. 64973-79-1D, aminoalkyl derivs. 70816-58-9D, Naphthyridine, aminoalkyl derivs. 70816-59-0D, Tetrazine, aminoalkyl derivs. 71012-22-1D, Naphthothiophene, aminoalkyl derivs. 85554-61-6D, Furanone, aminoalkyl derivs. 90151-97-6D, Perhydrocinnoline, aminoalkyl derivs. 96345-33-4D, Pyrone, aminoalkyl derivs. 96345-33-4D, Pyrone, furo derivs., aminoalkyl 99331-25-6D, Triazolopyrimidine, aminoalkyl derivs. 100324-81-0, Lisofylline 104534-79-4D, aminoalkyl derivs. 115825-13-3D, aminoalkyl derivs. 120366-15-6D, Benzisoquinoline, aminoalkyl derivs. 131689-44-6D, Triazinoindole, aminoalkyl derivs. 138459-63-9D, aminoalkyl derivs. 143349-20-6D, Benzothiazepine, aminoalkyl derivs. 161098-93-7D, aminoalkyl derivs. 167427-01-2D, aminoalkyl derivs. 167427-02-3D, aminoalkyl derivs. 167427-03-4D, aminoalkyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and agents for preventing tissue injury from hypoxia)

IT 167427-04-5D, aminoalkyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and agents for preventing tissue injury from hypoxia)
IT 60-33-3D, Linoleic acid, -contg. phosphatidic acids 544-63-8D, Myristic acid, phosphatidic acids contg. 9067-71-4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(method and agents for preventing tissue injury from hypoxia)
IT 8001-81-8D, Carboline (heterocycle), aminoalkyl derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and agents for preventing tissue injury m hypoxia)

L19 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
IC ICM A61K031-52
ICS A61K031-40; C07D473-06; C07D473-34; C07D403-12; C07D413-14; C07D031-495; C07D031-505
CC 1-6 (Pharmacology)
Section cross-reference(s): 10, 28
ST cytostatic heterocyclic compd; antimicrobial heterocyclic compd
IT Acquired immune deficiency syndrome
Allergy inhibitors
Alopecia
Antidiabetics and Hypoglycemics
Autoimmune disease
Cytotoxic agents
Fungicides and Fungistats
Immunosuppressants
Lupus erythematosus
Multiple sclerosis
Neoplasm inhibitors
Osteoporosis
Psoriasis
Sepsis and Septicemia
(compds. for treatment of proliferative diseases mediated by second messengers)
IT Cyclic compounds
Heterocyclic compounds
Lactams
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for treatment of proliferative diseases mediated by second messengers)
IT Basophil
Mast cell
(degranulation; compds. for treatment of proliferative diseases mediated by second messengers)
IT Blood vessel
(formation of; compds. for treatment of proliferative diseases mediated by second messengers)
IT Signal transduction, biological
(inhibition of IL-.beta.-induced; compds. for treatment of proliferative diseases mediated by second messengers)
IT **Transplant** and **Transplantation**
(rejection; compds. for treatment of proliferative diseases mediated by second messengers)
IT Acquired immune deficiency syndrome
(-related complex, compds. for treatment of proliferative diseases mediated by second messengers)
IT Hepatitis
(alc., compds. for treatment of proliferative diseases mediated by second messengers)
IT Inflammation inhibitors
(antiarthritics, compds. for treatment of proliferative diseases mediated by second messengers)
IT Bronchodilators
(antiasthmatics, compds. for treatment of proliferative diseases

mediated by second messengers)
IT Antiarteriosclerotics
(antiatherosclerotics, compds. for treatment of proliferative diseases mediated by second messengers)
IT Thyroid gland, disease
(autoimmune thyroiditis, compds. for treatment of proliferative diseases mediated by second messengers)
IT Artery, disease
(coronary, compds. for treatment of proliferative diseases mediated by second messengers)
IT Mental disorder
(dementia, HIV-assocd.; compds. for treatment of proliferative diseases mediated by second messengers)
IT Periodontium
(disease, compds. for treatment of proliferative diseases mediated by second messengers)
IT Connective tissue
(disease, scleroderma, compds. for treatment of proliferative diseases mediated by second messengers)
IT Sleep
(disorder, compds. for treatment of proliferative diseases mediated by second messengers)
IT Parturition
(disorder, premature, secondary to uterine infection; compds. for treatment of proliferative diseases mediated by second messengers)
IT Kidney, disease
(glomerulonephritis, compds. for treatment of proliferative diseases mediated by second messengers)
IT Quaternary ammonium compounds, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(heterocyclic, compds. for treatment of proliferative diseases mediated by second messengers)
IT Uterus, disease
(infection, premature parturition secondary to; compds. for treatment of proliferative diseases mediated by second messengers)
IT Intestine, disease
(inflammatory, compds. for treatment of proliferative diseases mediated by second messengers)
IT Lymphokines and Cytokines
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(interleukin 1.beta., antagonists; compds. for treatment of proliferative diseases mediated by second messengers)
IT Neoplasm inhibitors
(myelogenous leukemia, compds. for treatment of proliferative diseases mediated by second messengers)
IT Heterocyclic compounds
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nitrogen, compds. for treatment of proliferative diseases mediated by second messengers)
IT Artery, disease
(restenosis, compds. for treatment of proliferative diseases mediated by second messengers)
IT Shock
(septic, compds. for treatment of proliferative diseases mediated by second messengers)
IT Brain, disease
(stroke, compds. for treatment of proliferative diseases mediated by second messengers)
IT 53-86-1DP, Indomethacin, derivs. 55-21-0DP, Benzamide, derivs. 65-71-4DP, Thymine, derivs. 65-86-1DP, Orotic acid, derivs. 66-22-8DP, Uracil, derivs. 67-52-7DP, Barbituric acid, derivs. 69-72-7DP, Salicylic acid, derivs. 69-89-6DP, Xanthine, derivs. 69-93-2DP, Uric acid, derivs. 71-43-2DP, Benzene, derivs. 79-77-6DP, .beta.-Ionone,

derivs. 83-67-0DP, Theobromine, derivs. 85-41-6DP, Phthalimide, derivs. 91-18-9DP, Pteridine, derivs. 91-20-3DP, Naphthalene, derivs. **91-21-4DP**, derivs. 91-22-5DP, Quinoline, derivs. 92-52-4DP, Biphenyl, derivs. 106-51-4DP, 2,5-Cyclohexadiene-1,4-dione, derivs. 108-46-3DP, 1,3-Benzenediol, derivs. 109-97-7DP, Pyrrole, amides 110-82-7DP, Cyclohexane, derivs. 110-86-1DP, Pyridine, derivs. 110-89-4DP, Piperidine, derivs. 123-56-8DP, Succinimide, derivs. 132-86-5DP, 1,3-Dihydroxynaphthalene, derivs. 142-08-5DP, 2-Hydroxypyridine, derivs. 288-32-4DP, Imidazole, derivs. 289-95-2DP, Pyrimidine, derivs. 472-66-2DP, 2,6,6-Trimethyl-1-cyclohexene-1-acetaldehyde, derivs. 487-21-8DP, Lumazine, derivs. 491-30-5DP, 1(2H)-Isoquinolinone, derivs. 491-36-1DP, Quinazolin-4(3H)-one, derivs. 588-59-0DP, Stilbene, derivs. 611-59-6DP, 1,7-Dimethylxanthine, derivs. 615-77-0DP, 1-Methyluracil, derivs. 696-04-8DP, Dihydrothymine, derivs. 696-11-7DP, 1-Methyl-5,6-dihydrouracil, derivs. 1006-08-2DP, 7-Methylhypoxanthine, derivs. 1076-22-8DP, 3-Methylxanthine, derivs. 1121-89-7DP, Glutarimide, derivs. 1123-40-6DP, 3,3-Dimethylglutarimide, derivs. 1406-18-4DP, Vitamin E, derivs. 1444-94-6DP, Hexahydrophthalimide, derivs. 4456-77-3DP, Homophthalimide, derivs. 11103-57-4DP, Vitamin A, derivs. 12001-79-5DP, Vitamin K, derivs. 12654-97-6DP, Triazine, derivs. 27813-21-4DP, Tetrahydrophthalimide, derivs. 27942-00-3DP, Methyluracil, derivs. 28473-29-2DP, Cyclopentanedione, derivs. 29059-07-2DP, Tetralone, derivs. 30581-70-5DP, Cyclohexanedione, derivs. 35121-78-9DP, Prostacyclin, derivs. 38194-50-2DP, Sulindac, derivs. 50256-18-3DP, 1-Methyllumazine, derivs. 53126-65-1DP, Tricyclododecane, derivs. 56395-76-7P 79012-66-1P 93667-91-5P 109421-37-6DP, derivs. 159431-45-5DP, derivs. 159431-46-6DP, derivs. 159431-47-7P 159431-48-8P 159431-49-9P 159431-50-2P 159431-51-3P 159431-52-4P 159431-53-5P 159431-54-6P 159431-55-7P 159431-56-8P 159431-57-9P 159431-58-0P 159431-59-1P 159431-60-4P 159431-61-5P 159431-62-6P 159431-63-7P 159431-64-8P 159431-65-9P 159431-66-0P 159431-67-1P 159431-68-2P 159431-69-3P 159431-70-6P 159431-71-7P 159431-72-8P 161098-93-7DP, derivs. 161098-94-8DP, derivs. 161271-41-6DP, 2H-Quinolizinedione, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for treatment of proliferative diseases mediated by second messengers)

IT 83-67-0, Theobromine 86-96-4, Benzoyleneurea 2695-47-8, 1-Bromo-5-hexene 2695-48-9, 8-Bromo-1-octene 4160-72-9, 1-Methylthymine 4286-55-9 6493-05-6, Pentoxifylline 13019-22-2, 9-Decen-1-ol 89359-54-6, 9-Bromo-1-nonene 159431-78-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(compds. for treatment of proliferative diseases mediated by second messengers)

IT 604-50-2P 6493-06-7P 38975-41-6P 56395-71-2P 58999-18-1P 114640-35-6P 154719-57-0P 154755-53-0P 156918-08-0P 156918-13-7P 156918-28-4P 156918-35-3P 156918-57-9P 157523-33-6P 159431-73-9P 159431-74-0P 159431-75-1P 159431-76-2P 159431-77-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compds. for treatment of proliferative diseases mediated by second messengers)

L19 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
CC 14-1 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 9
ST prostate adenocarcinoma phosphorous metabolite; phosphate prostate adenocarcinoma
IT Animal tissue culture
(of prostate gland adenocarcinoma cells of human, phosphorus metabolite characterization in, NMR spectroscopy and HPLC in study of)
IT Nucleotides, biological studies
RL: BIOL (Biological study)
(diphosphates, of prostate gland adenocarcinoma cultured cells and

xenotransplants in nude mouse and in situ tissues of human, NMR spectroscopy and HPLC in study of)
IT Prostate gland
(neoplasm, adenocarcinoma, phosphorus metabolites characterization in cultured cells and xenotransplants in nude mouse and in situ from tissues of human, NMR spectroscopy and HPLC in study of)
IT Nucleotides, biological studies
RL: BIOL (Biological study)
(triphosphates, of prostate gland adenocarcinoma cultured cells and xenotransplants in nude mouse and in situ tissues of human, NMR spectroscopy and HPLC in study of)
IT **Transplant** and **Transplantation**
(xeno-, of prostate gland adenocarcinoma of human, in nude mouse, phosphorus metabolite characterization in, NMR spectroscopy and HPLC in study of)
IT 7723-14-0D, Phosphorus, metabolites
RL: PRP (Properties)
(characterization of, in cultured cells and xenotransplants in nude mouse and in situ in tissues of prostate gland adenocarcinoma of human, NMR spectroscopy and HPLC in study of)
IT 61-19-8, 5'-AMP, biological studies **407-41-0** 563-24-6, Glycerophosphocholine 1190-00-7, Glycerophosphoethanolamine 14265-44-2, Phosphate, biological studies
RL: BIOL (Biological study)
(of prostate gland adenocarcinoma cultured cells and xenotransplants in nude mouse and in situ from tissues of human, NMR spectroscopy and HPLC in study of)
IT 67-07-2, Phosphocreatine 107-73-3, Phosphocholine 133-89-1, UDP-glucose 528-04-1, Uridine-5'-diphospho-N-acetylglucosamine 1071-23-4, Phosphoethanolamine 2956-16-3, UDP-galactose 17479-06-0
RL: BIOL (Biological study)
(of prostate gland adenocarcinoma cultured cells and xenotransplants in nude mouse and in situ in tissues of human, NMR spectroscopy and HPLC in study of)

L19 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
CC 14-1 (Mammalian Pathological Biochemistry)
ST hepatoma phosphoserine phosphothreonine prostaglandin
IT Prostaglandins
RL: BIOL (Biological study)
(of hepatoma and prostate tumor tissues, phosphoserine and phosphothreonine in relation to)
IT Liver, neoplasm
(hepatoma, phosphoserine and phosphothreonine and prostaglandins of)
IT Prostate gland
(neoplasm, phosphoserine and phosphothreonine and prostaglandins of)
IT 1114-81-4
RL: BIOL (Biological study)
(of hepatoma and prostate tumor tissues, phosphoserine and prostaglandins in relation to)
IT **407-41-0**
RL: BIOL (Biological study)
(of hepatoma and prostate tumor tissues, phosphothreonine and prostaglandins in relation to)

L19 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
CC 6-3 (General Biochemistry)
Section cross-reference(s): 14
ST hepatocellular carcinoma glycophosphoprotein p65; tumor phosphoprotein p65
IT Amino acids, biological studies
RL: BIOL (Biological study)
(of tumor-assocd. glycophosphoprotein p65, of hepatocellular carcinoma)
IT Neoplasm, composition
(tumor-assocd. glycophosphoprotein p65 as marker for)
IT Glycophosphoproteins
RL: BIOL (Biological study)
(tumor-assocd., p65, of hepatocellular carcinoma, purifn. and

properties of)
IT Liver, neoplasm
(hepatoma, tumor-assocd. glycophosphoprotein p65 of, purifn. and properties of)
IT **407-41-0** 1114-81-4 21820-51-9, Phosphotyrosine
RL: BIOL (Biological study)
(of glycophosphoprotein p65, of hepatocellular carcinoma)